NovoCure Ltd (NASDAQ: NVCR) stock closed at $15.18 on 12/27/23 after a major increase of 12.2%. Moreover, unusually high trading volume at 152% of normal accompanied the advance. The stock has risen 13.3% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, NVCR is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. NovoCure has a very low Appreciation Score of 10 and a very low Power Rating of 6, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment